Company: NIVFW
Filing Date: 2025-09-18
Form Type: F-1
Source: 0001213900-25-088927
Chunk: 246

Company: NewGenIvf Group Ltd
Filing Date: 2025-09-18
Form: F-1
Chunk 246
---
 tranche, the Company sold to the investor a senior convertible note in the principal amount of $.
The Note bears an interest rate of % per annum and may be adjustable from time to time pursuant to its terms. The funding from
these arrangements with the investor is intended to be used to finance the establishment of a fertility clinic in Dubai.

Mr. Yip Eng Jeremy Foo,
a director of NewGenIvf Group Limited (the “Company”), has resigned from the Board of Directors of the Company, the Audit
Committee of the Company, and the Compensation Committee of the Company due to personal reasons, effective April 4, 2025. Mr. Foo’s
resignation did not result from any disagreement with the Board or the Company on any matter relating to the Company’s operations,
policies or practices.

Ms. Florianna Ann Chi Wan
Chan will be appointed as a director of the Company, effective April 15, 2025, to fill the vacancy on the Audit Committee and the Compensation
Committee created by Mr. Foo’s resignation. Ms Chan has over 20 years of experience in project management, real estate development,
and luxury hospitality, and is a proven leader in driving growth and operational excellence. Since 2015, Ms. Chan has led Lab Concept
Company Limited, a subsidiary of The Lane Crawford Joyce Group, where she successfully restructured operations, spearheaded rebranding,
and digitized processes, achieving significant revenue growth. Previously, she held senior roles at VCC Company Limited, Eton Properties,
and Crown Macau, excelling in real estate development, marketing, and VIP services. She holds a Bachelor of Hospitality Management from
Central Queensland University in Australia and an Advanced Diploma from William Angliss Institute of TAFE. Fluent in Cantonese, Mandarin,
and English, Ms. Chan brings a deep understanding of Asia Pacific markets and a strategic vision that will drive the Company’s
continued growth and success.

<div align='center'>F-32</div>

On April 15, 2025, the Board
of Directors approved another reverse stock split of all of the Company’s issued and unissued shares, including the Class A ordinary
shares with no par value (the “Class A Ordinary Shares”), Class B ordinary shares with no par value and preferred shares
with no par value, at an exchange ratio of one (1) share for ten (10) shares. The Reverse Stock Split became effective on May 5, 2025,
andits Class A Ordinary